IL194153A0 - Compounds for the treatment of spinal muscular atrophy and other uses - Google Patents
Compounds for the treatment of spinal muscular atrophy and other usesInfo
- Publication number
- IL194153A0 IL194153A0 IL194153A IL19415308A IL194153A0 IL 194153 A0 IL194153 A0 IL 194153A0 IL 194153 A IL194153 A IL 194153A IL 19415308 A IL19415308 A IL 19415308A IL 194153 A0 IL194153 A0 IL 194153A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- treatment
- muscular atrophy
- spinal muscular
- spinal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000002320 spinal muscular atrophy Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78329206P | 2006-03-17 | 2006-03-17 | |
| PCT/US2007/006772 WO2007109211A2 (en) | 2006-03-17 | 2007-03-16 | 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL194153A0 true IL194153A0 (en) | 2009-08-03 |
Family
ID=38477008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL194153A IL194153A0 (en) | 2006-03-17 | 2008-09-16 | Compounds for the treatment of spinal muscular atrophy and other uses |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8110681B2 (https=) |
| EP (1) | EP2027088A2 (https=) |
| JP (2) | JP2009530306A (https=) |
| CN (1) | CN101500995A (https=) |
| AU (1) | AU2007227398C1 (https=) |
| BR (1) | BRPI0708801A2 (https=) |
| CA (1) | CA2645426A1 (https=) |
| IL (1) | IL194153A0 (https=) |
| WO (1) | WO2007109211A2 (https=) |
| ZA (1) | ZA200807936B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2215074B1 (en) * | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| CN101903335A (zh) * | 2007-10-19 | 2010-12-01 | 詹森药业有限公司 | 连接有胺的γ-分泌酶调节剂 |
| JP5632612B2 (ja) * | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| JP5484316B2 (ja) * | 2008-02-28 | 2014-05-07 | 財団法人乙卯研究所 | 芳香族アミド誘導体 |
| US10793515B2 (en) | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| US20210130285A1 (en) | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| GB0909672D0 (en) * | 2009-06-04 | 2009-07-22 | Xention Discovery Ltd | Compounds |
| GB0909671D0 (en) * | 2009-06-04 | 2009-07-22 | Xention Discovery Ltd | Compounds |
| KR101758046B1 (ko) * | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
| JP6097998B2 (ja) * | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| WO2013062028A1 (ja) * | 2011-10-25 | 2013-05-02 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| DK2812004T3 (en) * | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| US9212209B2 (en) * | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| EP2921480B1 (en) * | 2012-11-19 | 2017-10-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| KR20150098675A (ko) * | 2012-12-24 | 2015-08-28 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 넌센스 돌연변이로부터 생긴 유전적 질환을 치료하기 위한 물질 및 이를 확인하는 방법 |
| WO2014134419A1 (en) | 2013-03-01 | 2014-09-04 | Gilead Sciences, Inc. | Use of ikach blockers for the treatment of cardiac diseases |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| SI3186241T1 (sl) | 2014-08-29 | 2021-03-31 | Chdi Foundation, Inc. | Sonde za slikanje Huntingtonovega proteina |
| CN105801556A (zh) * | 2014-12-31 | 2016-07-27 | 上海药谷药业有限公司 | 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法 |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| EP3322699B1 (en) * | 2015-07-14 | 2019-05-15 | H. Hoffnabb-La Roche Ag | 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| WO2018049328A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| JP7086942B2 (ja) | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| EA201991309A1 (ru) | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EP4004213A1 (en) | 2019-07-25 | 2022-06-01 | Novartis AG | Regulatable expression systems |
| KR102186761B1 (ko) | 2020-06-03 | 2020-12-04 | 옙바이오 주식회사 | 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물 |
| WO2022115301A1 (en) * | 2020-11-24 | 2022-06-02 | Merck Sharp & Dohme Corp. | Modified isoindolinones as glucosylceramide synthase inhibitors |
| CN115304472A (zh) * | 2022-06-27 | 2022-11-08 | 重庆医药高等专科学校 | 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的合成方法 |
| CN115141097A (zh) * | 2022-06-27 | 2022-10-04 | 重庆医药高等专科学校 | 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的生产线系统 |
| KR102883783B1 (ko) * | 2022-12-15 | 2025-11-12 | 옙바이오 주식회사 | 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 제조방법 |
| KR102597093B1 (ko) * | 2023-06-07 | 2023-11-03 | 옙바이오 주식회사 | 줄기세포 노화 억제 신규 화합물 및 이의 약학적 용도 |
| CN117740969B (zh) * | 2023-11-30 | 2025-01-10 | 杭州志呈科技有限公司 | 一种吲哚布芬杂质检测方法及其应用 |
| CN120965663A (zh) * | 2024-05-17 | 2025-11-18 | 北京理工大学 | sEH抑制剂化合物、药物组合物及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2034240C2 (de) | 1968-03-27 | 1982-12-02 | CIBA-GEIGY AG, 4002 Basel | Isoindolinderivate, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung |
| US4126691A (en) | 1968-03-27 | 1978-11-21 | Ciba-Geigy Corporation | Tertiary aminoacids |
| US3641040A (en) * | 1968-03-27 | 1972-02-08 | Ciba Geigy Corp | Tertiary amino phenyl acetic acids |
| US3542806A (en) | 1968-03-29 | 1970-11-24 | Robins Co Inc A H | 2-(1-substituted-3-pyrrolidinyl)-isoindolines |
| DE2046992A1 (en) * | 1970-09-24 | 1972-03-30 | Merck Patent Gmbh, 6100 Darmstadt | Isoindolinophenyl-alkanoic acid esters and salts - - antiphlogistic, antipyretic and analgesic agents |
| DE2154525A1 (de) * | 1970-11-05 | 1972-06-15 | Carlo Erba S.P.A., Mailand (Italien) | Isoindolinderivate und Verfahren zu ihrer Herstellung |
| FI53702C (fi) * | 1971-11-22 | 1978-07-10 | Erba Carlo Spa | Foerfarande foer framstaellning av isoindolinderivat |
| US3890346A (en) * | 1972-03-22 | 1975-06-17 | Monsanto Co | Process for the preparation of N-arylphthalimidines |
| GB1413173A (en) * | 1972-07-07 | 1975-11-12 | Bp Chem Int Ltd | Polymerisation process |
| US3997669A (en) | 1972-12-26 | 1976-12-14 | Ciba-Geigy Corporation | Tertiary aminoacids |
| JPS5233667A (en) * | 1975-09-11 | 1977-03-14 | Fuji Kagaku Kogyo Kk | Process for preparation of hydrogenated 1-oxo-isoindoline derivatives |
| IT1113035B (it) * | 1979-03-06 | 1986-01-20 | Erba Farmitalia | Esteri c alla 3 - c alla 4 aclhilici di 1-oxo-2- aperta par.graffa p aperta par. quadrata (alfa-metil) -carbossimetil chiusa par. quadrata - fenil chiusa par. graffa- isoindolina |
| JPS5644686A (en) | 1979-09-21 | 1981-04-23 | Hodogaya Chem Co Ltd | Pressure-sensitive reproducing paper |
| JPS5645955A (en) | 1979-09-21 | 1981-04-25 | Hodogaya Chem Co Ltd | 6-(2,3-dihydroisoindol-2-yl)fluoran compound |
| JPS5750960A (en) * | 1980-09-10 | 1982-03-25 | Hisamitsu Pharmaceut Co Inc | Preparation of novel 4- 1-oxo-2-isoindolinyl acetophenone |
| JPS5845088A (ja) | 1981-09-09 | 1983-03-16 | Sumitomo Chem Co Ltd | 記録紙 |
| JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
| JPH03181478A (ja) | 1989-12-08 | 1991-08-07 | Banyu Pharmaceut Co Ltd | ピリドンカルボン酸誘導体 |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5567718A (en) | 1994-08-11 | 1996-10-22 | Hoechst Marion Roussel Inc. | 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors |
| WO1998040061A1 (en) * | 1997-03-10 | 1998-09-17 | Loma Linda University Medical Center | Use of r-nsaid's for the prevention of alzheimer's disease |
| CA2355886C (en) | 1998-12-23 | 2006-10-31 | Schering Corporation | Substituted oximes and hydrazones as neurokinin antagonists |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| WO2002046164A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic compounds |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| WO2004036181A2 (en) | 2002-10-17 | 2004-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating neurological diseases and disorders |
| WO2004048332A1 (ja) | 2002-11-26 | 2004-06-10 | Maruishi Pharmaceutical Co., Ltd. | イソインドリン誘導体 |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| WO2006050451A2 (en) | 2004-11-02 | 2006-05-11 | Whitehead Institute For Biomedical Research | Methods and compositions to treat motor neuron disease |
| EA014428B1 (ru) | 2006-02-03 | 2010-12-30 | Глэксо Груп Лимитед | Производные бензоизоиндола для лечения боли |
| WO2008045905A1 (en) | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as iap inhibitors |
-
2007
- 2007-03-13 US US12/293,268 patent/US8110681B2/en not_active Expired - Fee Related
- 2007-03-16 JP JP2009500525A patent/JP2009530306A/ja active Pending
- 2007-03-16 BR BRPI0708801-9A patent/BRPI0708801A2/pt not_active IP Right Cessation
- 2007-03-16 CA CA002645426A patent/CA2645426A1/en not_active Abandoned
- 2007-03-16 CN CNA2007800155890A patent/CN101500995A/zh active Pending
- 2007-03-16 AU AU2007227398A patent/AU2007227398C1/en not_active Ceased
- 2007-03-16 EP EP07753404A patent/EP2027088A2/en not_active Withdrawn
- 2007-03-16 WO PCT/US2007/006772 patent/WO2007109211A2/en not_active Ceased
-
2008
- 2008-09-16 ZA ZA2008/07936A patent/ZA200807936B/en unknown
- 2008-09-16 IL IL194153A patent/IL194153A0/en unknown
-
2011
- 2011-12-05 US US13/310,965 patent/US20120083495A1/en not_active Abandoned
-
2013
- 2013-01-11 JP JP2013004082A patent/JP2013116901A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120083495A1 (en) | 2012-04-05 |
| US20090312323A1 (en) | 2009-12-17 |
| JP2013116901A (ja) | 2013-06-13 |
| AU2007227398C1 (en) | 2013-05-30 |
| BRPI0708801A2 (pt) | 2011-06-14 |
| WO2007109211A2 (en) | 2007-09-27 |
| AU2007227398A8 (en) | 2008-11-27 |
| JP2009530306A (ja) | 2009-08-27 |
| AU2007227398A1 (en) | 2007-09-27 |
| ZA200807936B (en) | 2009-12-30 |
| AU2007227398B2 (en) | 2012-09-27 |
| WO2007109211A3 (en) | 2007-12-13 |
| CA2645426A1 (en) | 2007-09-27 |
| CN101500995A (zh) | 2009-08-05 |
| US8110681B2 (en) | 2012-02-07 |
| WO2007109211A8 (en) | 2009-02-12 |
| EP2027088A2 (en) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200807936B (en) | Compounds for the treatment of spinal muscular atrophy and other uses | |
| GB0610867D0 (en) | Treatment of pain | |
| PL1978947T3 (pl) | Nitrooksypochodne do zastosowania w leczeniu dystrofii mięśniowych | |
| PL2086642T3 (pl) | DNaza do leczenia męskiej subpłodności | |
| IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
| IL193748A0 (en) | Treatment of pain | |
| SI2497500T1 (sl) | Genska terapija za spinalno mišično atrofijo | |
| IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
| PL1685834T3 (pl) | Zastosowanie kwasu pinolenowego do leczenia otyłości | |
| IL189270A0 (en) | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | |
| ZA200806808B (en) | Treatment of stressed patients | |
| EP2324041A4 (en) | PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | |
| GB0909297D0 (en) | Composition for the treatment of skin conditions | |
| IL187405A0 (en) | Methods and compositions for the treatment of pain | |
| IL197766A0 (en) | Use of oritavancin for the prevention and treatment of anthrax | |
| IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
| EP2124968A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE ATROPHY | |
| GB0602768D0 (en) | Treatment of muscular dystrophy | |
| GB0610868D0 (en) | Treatment of pain | |
| GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
| EP1962882A4 (en) | COMPOSITIONS AND METHOD FOR TREATING DIABETES | |
| ZA200710476B (en) | Methods and compositions for the treatment of pain | |
| GB0616450D0 (en) | Treatment of pain | |
| GB0602767D0 (en) | Treatment of muscular dystrophy | |
| HU0500947D0 (en) | Composition for treatment of paradontosis |